BR0207394A - Proteìna de fusão para a secreção de uma proteìna de interesse no sobrenadante da cultura bacteriana - Google Patents

Proteìna de fusão para a secreção de uma proteìna de interesse no sobrenadante da cultura bacteriana

Info

Publication number
BR0207394A
BR0207394A BR0207394-3A BR0207394A BR0207394A BR 0207394 A BR0207394 A BR 0207394A BR 0207394 A BR0207394 A BR 0207394A BR 0207394 A BR0207394 A BR 0207394A
Authority
BR
Brazil
Prior art keywords
protein
interest
secretion
culture supernatant
bacterial culture
Prior art date
Application number
BR0207394-3A
Other languages
English (en)
Other versions
BRPI0207394B8 (pt
BRPI0207394B1 (pt
Inventor
Paul Habermann
Johann Ertl
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0207394A publication Critical patent/BR0207394A/pt
Publication of BRPI0207394B1 publication Critical patent/BRPI0207394B1/pt
Publication of BRPI0207394B8 publication Critical patent/BRPI0207394B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROTEìNA DE FUSãO PARA A SECREçãO DE UMA PROTEìNA DE INTERESSE NO SOBRENADANTE DA CULTURA BACTERIANA". A invenção refere-se a proteínas de fusão compreendendo uma parte de fusão e uma proteína de interesse, a combinação das duas proteínas conduzindo à proteína de fusão sendo secretada no sobrenadante de um hospedeiro bacteriano e a proteína de interesse estando presente em sua correta estrutura tridimensional.
BRPI0207394A 2001-02-20 2002-02-08 dna codificando uma proteína de fusão proteína codificada por um dna, plasmídeo, micro-organismo hospedeiro, processo para a produção fermentativa de uma proteína de fusão e processo para a produçao de insulina BRPI0207394B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10108212A DE10108212A1 (de) 2001-02-20 2001-02-20 Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
PCT/EP2002/001307 WO2002068660A1 (en) 2001-02-20 2002-02-08 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Publications (3)

Publication Number Publication Date
BR0207394A true BR0207394A (pt) 2004-02-10
BRPI0207394B1 BRPI0207394B1 (pt) 2015-06-16
BRPI0207394B8 BRPI0207394B8 (pt) 2021-05-25

Family

ID=7674913

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0207394A BRPI0207394B8 (pt) 2001-02-20 2002-02-08 dna codificando uma proteína de fusão proteína codificada por um dna, plasmídeo, micro-organismo hospedeiro, processo para a produção fermentativa de uma proteína de fusão e processo para a produçao de insulina

Country Status (19)

Country Link
EP (1) EP1364029B1 (pt)
JP (1) JP4243104B2 (pt)
KR (1) KR100858009B1 (pt)
CN (1) CN100500853C (pt)
AT (1) ATE314480T1 (pt)
AU (1) AU2002231784B2 (pt)
BR (1) BRPI0207394B8 (pt)
CA (1) CA2438886C (pt)
DE (2) DE10108212A1 (pt)
DK (1) DK1364029T3 (pt)
ES (1) ES2254658T3 (pt)
HK (1) HK1065335A1 (pt)
IL (1) IL157414A0 (pt)
MX (1) MXPA03007114A (pt)
NO (1) NO331271B1 (pt)
NZ (1) NZ527643A (pt)
PE (1) PE20020876A1 (pt)
WO (1) WO2002068660A1 (pt)
ZA (1) ZA200305869B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP5028551B2 (ja) 2003-11-21 2012-09-19 フェネックス インコーポレイテッド Ｓｅｃ系分泌によって改良された発現系
ES2707786T3 (es) 2004-01-16 2019-04-05 Pfenex Inc Expresión de proteínas de mamífero en Pseudomonas fluorescens
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
AU2008210538B2 (en) 2007-01-31 2013-06-06 Pelican Technology Holdings, Inc. Bacterial leader sequences for increased expression
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR101530395B1 (ko) 2007-04-27 2015-06-19 피페넥스 인크. 향상된 수율 및(또는) 품질로 이종 단백질을 발현하는 특정 균주를 동정하기 위해 미생물 숙주를 신속히 스크리닝하는 방법
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0907371A2 (pt) 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
NZ586589A (en) 2008-01-09 2012-04-27 Sanofi Aventis Deutschland Novel insulin analogues having an extremely delayed time-action profile
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2010038145A2 (en) * 2008-10-02 2010-04-08 Unitargeting Research As Kit for the optimisation of protein synthesis/secretion
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
ES2853935T3 (es) 2013-03-12 2021-09-20 Massachusetts Gen Hospital Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
WO2015089321A2 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004418A1 (fr) * 1984-03-27 1985-10-10 Transgene S.A. Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
AU648124B2 (en) * 1990-11-08 1994-04-14 Japan Energy Corporation Hirudine mutant, production thereof, anticoagulant, secretory vector, microorganism transformed by said vector, and production of product from said microorganism
WO1995009125A1 (en) * 1992-09-28 1995-04-06 Pehr Harold T Kicker latch for container closures
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP

Also Published As

Publication number Publication date
AU2002231784B2 (en) 2006-10-26
BRPI0207394B8 (pt) 2021-05-25
WO2002068660A1 (en) 2002-09-06
BRPI0207394B1 (pt) 2015-06-16
CA2438886C (en) 2013-07-23
NO20033673D0 (no) 2003-08-19
CN100500853C (zh) 2009-06-17
EP1364029A1 (en) 2003-11-26
JP2004518444A (ja) 2004-06-24
JP4243104B2 (ja) 2009-03-25
ATE314480T1 (de) 2006-01-15
NZ527643A (en) 2005-07-29
IL157414A0 (en) 2004-03-28
CA2438886A1 (en) 2002-09-06
DE10108212A1 (de) 2002-08-22
KR100858009B1 (ko) 2008-09-11
DK1364029T3 (da) 2006-05-08
KR20030074842A (ko) 2003-09-19
EP1364029B1 (en) 2005-12-28
CN1529757A (zh) 2004-09-15
HK1065335A1 (en) 2005-02-18
ES2254658T3 (es) 2006-06-16
MXPA03007114A (es) 2003-11-18
DE60208343T2 (de) 2006-06-22
DE60208343D1 (de) 2006-02-02
NO20033673L (no) 2003-10-17
NO331271B1 (no) 2011-11-14
ZA200305869B (en) 2004-06-25
PE20020876A1 (es) 2002-11-05

Similar Documents

Publication Publication Date Title
BR0207394A (pt) Proteìna de fusão para a secreção de uma proteìna de interesse no sobrenadante da cultura bacteriana
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
DE60144145D1 (de) Subtilisin-variante
PT1171143E (pt) Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
TR200100056T2 (tr) Nörotrofik faktörler
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
ATE439441T1 (de) Veränderte, fluoreszierende proteine
ATE435916T1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
DK1209985T3 (da) Modification af proteiners skumningsegenskaber
AU2002349231A1 (en) Methylotrophic bacterium for the production of recombinant proteins and other products
DE60118935D1 (de) Dna & protein bindende miniatur proteine
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
WO2006097708A3 (en) Affinity purification of protein
WO2006035311A3 (en) Group a streptococcus crge protein
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DE60235809D1 (de) Nukleinsäurefreie ghost zusammensetzungen
AU2003226907A1 (en) Method for the preparation of recombinant mammalian heparin-binding protein (hbp)
AU2002337248A1 (en) Nucleic acids coding for novel fbox proteins, their diagnostic and therapeutic uses
AU2003287108A1 (en) Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production
AU2002303137A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
TW200504218A (en) Methods for preventing gluconoylation of proteins
DK1472342T3 (da) Med OXA1P forbedret proteinsekretion
AU2002228599A1 (en) Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/06/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/02/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/02/2022